SecBot SecBot
Insider Cluster (3 insiders) ·Filed Aug 18, 2026

CORT

CORCEPT THERAPEUTICS INC
BEARISH
Impact 4/10
Horizonweeks Processed2mo ago
Insider cluster: 3 insiders, $1.8M total
Actionable Insight ▼ Bearish

The cluster of C-suite selling, while small in proportion to market cap, is a modest negative signal ahead of the upcoming FDA decision on relacorilant. Monitor for any additional insider sales or negative pre-announcements.

DirectionBearish
Confidencemedium
Horizonweeks

Lifyorli

▲ Bullish Named in this insider cluster
Impact
Phase
Approved
Time to market
Lifyorli is already approved and commercially available in the U.S. for platinum-resistant ovarian cancer (approved March 25, 2026). A decision on the Cushing's syndrome indication is expected by December 17, 2026. A Marketing Authorization Application (MAA) is also under review by the European Medicines Agency.
Next catalyst
PDUFA date · Dec 17, 2026 31d

What to watchThe next major catalyst is the December 17, 2026 PDUFA decision on relacorilant's NDA resubmission for Cushing's syndrome. An approval would open a large endocrinology market (currently served by Korlym, which generated ~$498M in the first nine months of 2026) and could significantly expand the drug's total addressable market beyond the already-approved ovarian cancer indication. A second CRL would be a major setback for the Cushing's franchise.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$119.02
T+0 close · Aug 18, 2026 · via day close
Latest settled
−38.07%
T+60 · $73.71
Vs SPY
−36.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 19 $119.02entry
  2. T+1 · 3mo ago +1.71%α +2.55% · $121.05
  3. T+5 · 3mo ago +0.66%α +1.04% · $119.80
  4. T+20 · 2mo ago −3.50%α −2.66% · $114.86
  5. T+60 · 4d ago −38.07%α −36.52% · $73.71
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three Corcept insiders, including the Chief Business Officer and Chief Development Officer, sold a total of $1.82M in open-market sales over a week. The CBO's $1.16M sale is the largest single transaction. While the dollar amount is modest relative to CORT's $12.7B market cap (~0.014%), the cluster of C-suite selling warrants attention, especially given the stock's strong recent performance and the company's upcoming catalyst (FDA decision on relacorilant).

Key Financial Metrics

Direction
selling
Total Value
$1.8M
Insiders
3

Key Facts

  • Three insiders sold a total of $1.82M in open-market sales over a week.
  • Chief Business Officer Robb Gary Charles sold $1.16M on August 17.
  • Chief Development Officer Guyer William sold $544K on August 10.
  • Total sales represent ~0.014% of CORT's $12.7B market cap.
  • The cluster includes C-suite executives, which carries more weight than director-level sales.

Financial Impact

Insider sales of $1.82M, representing 0.014% of market cap

insider ownership

Risk Factors

  • Insider sales may signal management's view that the stock is fully valued ahead of a binary catalyst.
  • The FDA decision on relacorilant (expected Q4 2026) is a high-stakes event that could drive significant volatility.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CORT-1787119850986

Track record

36 reports on CORT

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
  2. Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
  3. Nov 4, 202611d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
  5. Nov 2, 202613d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
  7. Oct 5, 20265w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
  8. Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
  9. Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
  10. Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Tue (16h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 19, 2026